Lung Cancer Clinical Trial

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

Summary

The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected stage I or II (Stage IIB N0, M0) non-small cell lung cancer (NSCLC).

The primary study hypotheses are:

SBRT plus pembrolizumab prolongs Event-free Survival (EFS) compared to SBRT plus placebo (normal saline solution), and
SBRT plus pembrolizumab prolongs Overall Survival (OS) compared to SBRT plus placebo.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has previously untreated non-small cell lung cancer (NSCLC) diagnosed by histology or cytology and confirmed as Stage I or II (T1 to limited T3, N0, M0) NSCLC (American Joint Committee on Cancer, AJCC) by chest computed tomography (CT) and positron emission tomography (PET) scan. Participants with pericardium invasion, >2 nodules or 2 nodules that cannot be treated in one field (>2 cm apart and/or total planned target volume [PTV] >163 cc) and diaphragm elevation suggestive of phrenic nerve invasion are excluded
Cannot undergo thoracic surgery due to existing medical illness(es) as determined by the site's multi-disciplinary tumor board. Medically operable participants who decide to treat with stereotactic body radiotherapy (SBRT) as definitive therapy rather than surgery are also eligible, if patient's unwillingness to undergo surgical resection is clearly documented
Has a Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
Is able to receive SBRT and does not have an ultra-centrally located tumor
Has adequate organ function within 7 days prior to the start of study treatment
A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: a) not a women of childbearing potential (WOCBP) OR b) A WOCBP and uses contraceptive method that is highly effective (with a failure rate of <1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose
Male participants are eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of radiotherapy: refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent or must agree to use contraception per study protocol, unless confirmed to be azoospermic
Has a radiation therapy plan approved by the central radiation therapy quality assurance vendor

Exclusion Criteria:

Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4], tumor necrosis factor receptor superfamily member 4 [OX-40], tumor necrosis factor receptor superfamily member 9 [CD137])
Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast
Has received a live vaccine within 30 days prior to the first dose of study intervention
Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention administration
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. A prior NSCLC that occurred and was treated curatively at least 2 years prior to the date of the current diagnosis would be considered a separate primary lung cancer, and therefore an additional malignancy. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast c carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
Has a known hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has an active autoimmune disease that has required systemic treatment in past 2 years, except replacement therapy
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose
Have not adequately recovered from major surgery or have ongoing surgical complications
Has had an allogenic tissue/solid organ transplant

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

530

Study ID:

NCT03924869

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 180 Locations for this study

See Locations Near You

University of Alabama ( Site 0099)
Birmingham Alabama, 35233, United States
Infirmary Cancer Care ( Site 3044)
Mobile Alabama, 36607, United States More Info
Study Coordinator
Contact
251-435-6582
Banner MD Anderson Cancer Center ( Site 3029)
Gilbert Arizona, 85234, United States More Info
Study Coordinator
Contact
480-256-6444
CARTI Cancer Center ( Site 3045)
Little Rock Arkansas, 72205, United States More Info
Study Coordinator
Contact
501-366-1163
USC Norris Comprehensive Cancer Center ( Site 0007)
Los Angeles California, 90033, United States
Veterans Affairs Palo Alto Health Care System ( Site 3039)
Palo Alto California, 94304, United States More Info
Study Coordinator
Contact
650-239-2820
National Jewish Health ( Site 0010)
Denver Colorado, 80206, United States More Info
Study Coordinator
Contact
303-398-1233
Yale University ( Site 0011)
New Haven Connecticut, 06510, United States
Mid Florida Hematology and Oncology Center ( Site 0067)
Orange City Florida, 32763, United States More Info
Study Coordinator
Contact
386-774-1223
H. Lee Moffitt Cancer Center and Research Institute ( Site 0016)
Tampa Florida, 33612, United States
Goshen Center for Cancer Care ( Site 0022)
Goshen Indiana, 46526, United States More Info
Study Coordinator
Contact
574-364-2649
Franciscan Health Indianapolis ( Site 0024)
Indianapolis Indiana, 46237, United States More Info
Study Coordinator
Contact
317-528-7685
University of Kentucky School of Medicine & Hospitals ( Site 0026)
Lexington Kentucky, 40536, United States More Info
Study Coordinator
Contact
859-323-0250
Sinai Hospital of Baltimore ( Site 3011)
Baltimore Maryland, 21215, United States
William E. Kahlert Regional Cancer Center ( Site 3031)
Westminster Maryland, 21157, United States
Massachusetts General Hospital-Cancer Center Protocol Office ( Site 3007)
Boston Massachusetts, 02114, United States More Info
Study Coordinator
Contact
617-724-3661
Mass General / North Shore Center for Outpatient Care ( Site 3040)
Danvers Massachusetts, 01923, United States More Info
Study Coordinator
Contact
617-724-3661
University of Massachusetts ( Site 0029)
Worcester Massachusetts, 01655, United States
Sanford Bemidji ( Site 0080)
Bemidji Minnesota, 56601, United States
University of Minnesota ( Site 0069)
Minneapolis Minnesota, 55455, United States
St. Vincent Healthcare Frontier Cancer Center ( Site 3012)
Billings Montana, 59102, United States More Info
Study Coordinator
Contact
406-238-6685
John Theurer Cancer Center at Hackensack University Medical Center ( Site 3036)
Hackensack New Jersey, 07601, United States More Info
Study Coordinator
Contact
551-996-5809
Rutgers Cancer Institute of New Jersey ( Site 0043)
New Brunswick New Jersey, 08903, United States
Hematology-Oncology Associates of CNY ( Site 3055)
East Syracuse New York, 13057, United States More Info
Study Coordinator
Contact
315-472-7504
Mount Sinai Hospital ( Site 0046)
New York New York, 10029, United States
White Plains Hospital ( Site 3014)
White Plains New York, 10601, United States More Info
Study Coordinator
Contact
914-849-7500
Sanford Health Roger Maris Cancer Center ( Site 0079)
Fargo North Dakota, 58102, United States
Lehigh Valley Hospital- Cedar Crest ( Site 3005)
Allentown Pennsylvania, 18103, United States
St. Luke's University Health Network ( Site 3006)
Bethlehem Pennsylvania, 18015, United States More Info
Study Coordinator
Contact
484-526-7000
Penn State University Milton S. Hershey Medical Center ( Site 0064)
Hershey Pennsylvania, 17033, United States More Info
Study Coordinator
Contact
717-531-5471
Fox Chase Cancer Center ( Site 0051)
Philadelphia Pennsylvania, 19111, United States
Allegheny General Hospital ( Site 3028)
Pittsburgh Pennsylvania, 15212, United States More Info
Study Coordinator
Contact
412-359-6137
Lankenau Medical Center ( Site 3041)
Wynnewood Pennsylvania, 19096, United States More Info
Study Coordinator
Contact
484-476-8426
Sanford Cancer Center Oncology Clinic ( Site 0053)
Sioux Falls South Dakota, 57104, United States More Info
Study Coordinator
Contact
605-312-3320
University of Tennessee Medical Center Knoxville ( Site 3010)
Knoxville Tennessee, 37920, United States More Info
Study Coordinator
Contact
865-305-4893
Vanderbilt University Medical Center ( Site 0075)
Nashville Tennessee, 37232, United States More Info
Study Coordinator
Contact
615-875-0060
Cancer Care Northwest ( Site 0063)
Spokane Valley Washington, 99216, United States
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0206)
ABB Caba, C1199, Argentina More Info
Study Coordinator
Contact
54 114959 0200 ext 8159
Hospital Britanico de Buenos Aires ( Site 0204)
Buenos Aires Caba, C1280, Argentina More Info
Study Coordinator
Contact
+5491121571056
Sanatorio Parque ( Site 0207)
Rosario Santa Fe, S2000, Argentina More Info
Study Coordinator
Contact
+5493416955611
Hospital Provincial del Centenario ( Site 0205)
Rosario Santa Fe, S2002, Argentina More Info
Study Coordinator
Contact
+5493413702439
IDIM Instituto de Diagnostico e Investigaciones Metabolicas ( Site 0208)
Buenos Aires , C1012, Argentina More Info
Study Coordinator
Contact
+549-1141625353
Hospital Aleman ( Site 0200)
Buenos Aires , C1118, Argentina More Info
Study Coordinator
Contact
+541148277000
Instituto Medico Especializado Alexander Fleming ( Site 0203)
Buenos Aires , C1426, Argentina More Info
Study Coordinator
Contact
+5491166936669
CEMIC ( Site 0201)
Buenos Aires , C1431, Argentina More Info
Study Coordinator
Contact
+5411529901002543
Port Macquarie Base Hospital ( Site 2500)
Port Macquarie New South Wales, 2444, Australia
GenesisCare North Shore ( Site 2508)
St Leonards New South Wales, 2065, Australia More Info
Study Coordinator
Contact
61294631172
Royal Brisbane and Women s Hospital ( Site 2502)
Herston Queensland, 4029, Australia More Info
Study Coordinator
Contact
+61736467983
Icon Cancer Centre Hobart ( Site 2507)
Hobart Tasmania, 7000, Australia More Info
Study Coordinator
Contact
+61 407 110 474
Austin Health ( Site 2501)
Melbourne Victoria, 3084, Australia
Keppler Universitatsklinikum ( Site 0806)
Linz Oberosterreich, 4021, Austria More Info
Study Coordinator
Contact
+4373278066910
Landeskrankenhaus - Universitatsklinikum Graz ( Site 0804)
Graz Steiermark, 8036, Austria
Universitatsklinik LKH Innsbruck ( Site 0802)
Innsbruck Tirol, 6020, Austria More Info
Study Coordinator
Contact
+4351250481058
Social Medical Center - Otto Wagner Hospital ( Site 0801)
Vienna Wien, 1145, Austria More Info
Study Coordinator
Contact
+4319106042003
Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0318)
Porto Alegre Rio Grande Do Sul, 90050, Brazil More Info
Study Coordinator
Contact
+5551999818669
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 0301)
Porto Alegre Rio Grande Do Sul, 90610, Brazil More Info
Study Coordinator
Contact
+555133203039
Hospital e Maternidade Celso Pierro ( Site 0313)
Campinas Sao Paulo, 13060, Brazil
Instituto Nacional Do Cancer Jose Alencar Gomes Da Silva ( Site 0305)
Rio de Janeiro , 20231, Brazil More Info
Study Coordinator
Contact
+552132076564
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0300)
Sao Paulo , 01246, Brazil More Info
Study Coordinator
Contact
+551138932615
Hospital Paulistano - Amil Clinical Research ( Site 0316)
Sao Paulo , 01321, Brazil More Info
Study Coordinator
Contact
+552132071657
A.C. Camargo Cancer Center ( Site 0312)
Sao Paulo , 01509, Brazil More Info
Study Coordinator
Contact
+551121895021
Moncton Hospital - Horizon Health Network ( Site 0105)
Moncton New Brunswick, E1C 6, Canada More Info
Study Coordinator
Contact
5068575669
Kingston Health Sciences Centre ( Site 0100)
Kingston Ontario, K7L 2, Canada More Info
Study Coordinator
Contact
6135496666
Trillium Health Partners - Credit Valley Hospital ( Site 0102)
Mississauga Ontario, L5M 2, Canada More Info
Study Coordinator
Contact
905-813-4299
The Ottawa Hospital ( Site 0104)
Ottawa Ontario, K1H 8, Canada More Info
Study Coordinator
Contact
613737770070175
Sault Area Hospital ( Site 0101)
Sault Ste Marie Ontario, P6B 0, Canada More Info
Study Coordinator
Contact
7057593434
Health Sciences North Research Institute ( Site 0107)
Sudbury Ontario, P3E 5, Canada
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0110)
Montreal Quebec, H1T 2, Canada More Info
Study Coordinator
Contact
15142523400
McGill University Health Centre ( Site 0113)
Montréal Quebec, H4A 3, Canada More Info
Study Coordinator
Contact
514-934-1934
CHUS - Hopital Fleurimont ( Site 0111)
Sherbrooke Quebec, J1H 5, Canada More Info
Study Coordinator
Contact
819-346-1110
CHU Poitiers ( Site 1109)
Poitiers Ain, 86021, France More Info
Study Coordinator
Contact
+33549444538
CHU de Brest -Site Hopital Morvan ( Site 1100)
Brest Finistere, 29200, France More Info
Study Coordinator
Contact
+33298223578
Institut Bergonie ( Site 1102)
Bordeaux Gironde, 33076, France More Info
Study Coordinator
Contact
+33556333229
Institut Regional du Cancer de Montpellier - ICM ( Site 1108)
Montpellier Herault, 34298, France More Info
Study Coordinator
Contact
+33467612581
CHU de Rouen ( Site 1113)
Rouen Seine-Maritime, 76000, France More Info
Study Coordinator
Contact
+33232888990
Hopital Sud du Amiens ( Site 1115)
Amiens Somme, 80054, France More Info
Study Coordinator
Contact
+33322455902
Institut Curie ( Site 1112)
Paris , 75005, France More Info
Study Coordinator
Contact
+33144324606
Hopital Cochin ( Site 1107)
Paris , 75014, France More Info
Study Coordinator
Contact
+33158413091
A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 1114)
Paris , 75877, France More Info
Study Coordinator
Contact
+33140257502
Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1208)
Esslingen Baden-Wurttemberg, 73730, Germany More Info
Study Coordinator
Contact
0049 711 3103 865109
Universitaetsklinikum Heidelberg. ( Site 1204)
Heidelberg Baden-Wurttemberg, 69126, Germany More Info
Study Coordinator
Contact
+4962213968359
Pius Hospital Oldenburg ( Site 1202)
Oldenburg Baden-Wurttemberg, 26121, Germany More Info
Study Coordinator
Contact
+494412291610
Universitaetsklinikum Erlangen ( Site 1209)
Erlangen Bayern, 91054, Germany More Info
Study Coordinator
Contact
0049 9131 8533968
UKGM Gießen/Marburg-Medical Clinic V ( Site 1210)
Gießen Hessen, 35392, Germany More Info
Study Coordinator
Contact
+49 (0)641 985 59253
Universitaetsklinikum Essen ( Site 1201)
Essen Nordrhein-Westfalen, 45147, Germany
Evangelisches Krankenhaus Hamm gGmbH ( Site 1205)
Hamm Nordrhein-Westfalen, 59063, Germany More Info
Study Coordinator
Contact
+4923819058326
Charite Universitaetsmedizin Berlin ( Site 1207)
Berlin , 13353, Germany More Info
Study Coordinator
Contact
+4930450553044
Bacs-Kiskun Megyei Korhaz ( Site 2311)
Kecskemet Bacs-Kiskun, 6000, Hungary More Info
Study Coordinator
Contact
+3676516719
Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 2314)
Pécs Baranya, 7624, Hungary More Info
Study Coordinator
Contact
+36205264756
CRU Hungary KFT ( Site 2309)
Miskolc Borsod-Abauj-Zemplen, 3529, Hungary
Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz ( Site 2312)
Szekesfehervar Fejer, 8000, Hungary More Info
Study Coordinator
Contact
+3622535722
Petz Aladar Megyei Oktato Korhaz ( Site 2305)
Gyor Gyor-Moson-Sopron, 9024, Hungary More Info
Study Coordinator
Contact
+36309758356
Debreceni Egyetem Klinikai Kozpont ( Site 2301)
Debrecen Hajdu-Bihar, 4032, Hungary More Info
Study Coordinator
Contact
+3652255222
Jasz - Nagykun Szolnok megyei Hetenyi Geza Korhaz - Rendelointezet ( Site 2310)
Szolnok Jasz-Nagykun-Szolnok, 5004, Hungary More Info
Study Coordinator
Contact
+36209323256
Tudogyogyintezet Torokbalint ( Site 2302)
Torokbalint Pest, 2045, Hungary More Info
Study Coordinator
Contact
+36307005601
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 2307)
Kaposvar Somogy, 7400, Hungary More Info
Study Coordinator
Contact
+36703685838
Veszprem Megyei Tudogyogyintezet ( Site 2313)
Farkasgyepu Veszprem, 8582, Hungary More Info
Study Coordinator
Contact
+3689358013
Semmelweis University ( Site 2303)
Budapest , 1085, Hungary More Info
Study Coordinator
Contact
+3613558682
Orszagos Koranyi Pulmonologiai Intezet ( Site 2304)
Budapest , 1121, Hungary More Info
Study Coordinator
Contact
+36703288101
Orszagos Koranyi Pulmonologiai Intezet ( Site 2306)
Budapest , 1121, Hungary More Info
Study Coordinator
Contact
+36302005233
Orszagos Onkologiai Intezet ( Site 2308)
Budapest , 1122, Hungary More Info
Study Coordinator
Contact
+3612248600
Ospedale Santissima Annunziata ( Site 1303)
Chieti , 66100, Italy
A.O. Universitaria Careggi ( Site 1301)
Firenze , 50134, Italy More Info
Study Coordinator
Contact
+39055794111
Policlinico di Modena ( Site 1306)
Modena , 41124, Italy More Info
Study Coordinator
Contact
+39594224385
Policlinico Agostino Gemelli ( Site 1302)
Roma , 00168, Italy More Info
Study Coordinator
Contact
+390630155440
Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1309)
Roma , 00185, Italy More Info
Study Coordinator
Contact
+393476063165
Aichi Cancer Center Hospital ( Site 2804)
Nagoya Aichi, 464-8, Japan More Info
Study Coordinator
Contact
+81527626111
National Cancer Center Hospital East ( Site 2800)
Kashiwa Chiba, 27785, Japan More Info
Study Coordinator
Contact
+81471331111
Kurume University Hospital ( Site 2815)
Kurume Fukuoka, 830-0, Japan More Info
Study Coordinator
Contact
81942317200
Kobe Minimally Invasive Cancer Center ( Site 2811)
Kobe Hyogo, 650-0, Japan More Info
Study Coordinator
Contact
+81-78-304-4100
University of Tsukuba Hospital ( Site 2809)
Tsukuba Ibaraki, 305-8, Japan More Info
Study Coordinator
Contact
+81298533900
Sendai Kousei Hospital ( Site 2814)
Sendai Miyagi, 980-0, Japan More Info
Study Coordinator
Contact
+81-22-222-6181
Kansai Medical University Hospital ( Site 2808)
Hirakata Osaka, 573-1, Japan More Info
Study Coordinator
Contact
+81728040101
Osaka Medical and Pharmaceutical University Hospital ( Site 2813)
Takatsuki Osaka, 569-8, Japan More Info
Study Coordinator
Contact
+81-72-683-1221
University of Yamanashi Hospital ( Site 2807)
Chuo Yamanashi, 409-3, Japan More Info
Study Coordinator
Contact
+81552731111
Chiba University Hospital ( Site 2806)
Chiba , 260-8, Japan More Info
Study Coordinator
Contact
+81432227171
National Hospital Organization Kyushu Cancer Center ( Site 2816)
Fukuoka , 811-1, Japan More Info
Study Coordinator
Contact
+81925413231
Hiroshima University Hospital ( Site 2810)
Hiroshima , 73485, Japan More Info
Study Coordinator
Contact
+81822575555
Niigata Cancer Center Hospital ( Site 2801)
Niigata , 951-8, Japan More Info
Study Coordinator
Contact
+81252665111
Osaka International Cancer Institute ( Site 2812)
Osaka , 541-8, Japan More Info
Study Coordinator
Contact
+81-6-6945-1181
Tokyo Metropolitan Komagome Hospital ( Site 2802)
Tokyo , 113-8, Japan More Info
Study Coordinator
Contact
+81338232101
The Cancer Institute Hospital of JFCR ( Site 2803)
Tokyo , 135-8, Japan More Info
Study Coordinator
Contact
+81335200111
Showa University Hospital ( Site 2805)
Tokyo , 142-8, Japan More Info
Study Coordinator
Contact
+81337848000
Chungbuk National University Hospital ( Site 2605)
Cheongju-si Chungbuk, 28644, Korea, Republic of More Info
Study Coordinator
Contact
+82432696015
National Cancer Center ( Site 2604)
Goyang-si Kyonggi-do, 10408, Korea, Republic of More Info
Study Coordinator
Contact
+82319201694
The Catholic University of Korea St. Vincent s Hospital ( Site 2606)
Gyeonggi-do Kyonggi-do, 16247, Korea, Republic of More Info
Study Coordinator
Contact
+82312498153
Seoul National University Hospital ( Site 2600)
Seoul , 03080, Korea, Republic of
Samsung Medical Center ( Site 2603)
Seoul , 06351, Korea, Republic of More Info
Study Coordinator
Contact
+82234103609
Tergooiziekenhuizen, locatie Hilversum-Oncology ( Site 1407)
Hilversum Noord-Holland, 1213 , Netherlands More Info
Study Coordinator
Contact
+31887531753
Meander Medisch Centrum-Studie Team Oncologie ( Site 1403)
Amersfoort Utrecht, , Netherlands More Info
Study Coordinator
Contact
+31338507843
Auckland City Hospital ( Site 2900)
Grafton Auckland, 1023, New Zealand
St Olavs Hospital ( Site 1504)
Trondheim Sor-Trondelag, 7030, Norway
Helse Bergen HF Haukeland Universitetssykehus ( Site 1502)
Bergen Vestfold, 5021, Norway More Info
Study Coordinator
Contact
+4755973245
Oslo Universitetssykehus HF Ulleval Sykehus ( Site 1500)
Oslo , 0450, Norway More Info
Study Coordinator
Contact
+4722934809
Centrum Onkologii im. prof. Franciszka ukaszczyka-Ambulatorium Chemioterapii ( Site 2407)
Bydgoszcz Kujawsko-pomorskie, 85796, Poland More Info
Study Coordinator
Contact
523743525
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 2402)
Lodz Lodzkie, 93-51, Poland More Info
Study Coordinator
Contact
+48426895551
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie ( Site 2400)
Krakow Malopolskie, 31-82, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warszawa Mazowieckie, 02-78, Poland More Info
Study Coordinator
Contact
+48225463066
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2403)
Gliwice Slaskie, 44-10, Poland More Info
Study Coordinator
Contact
+48322788805
SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2404)
Olsztyn Warminsko-mazurskie, 10-22, Poland More Info
Study Coordinator
Contact
+48895398527
Chelyabinsk Regional Clinical Oncology Dispensary ( Site 2014)
Chelyabinsk Chelyabinskaya Oblast, 45408, Russian Federation
GUZ Lipetsk Regional Oncology Dispensary ( Site 2010)
Lipetsk Lipetskaya Oblast, 39800, Russian Federation
N.N.Blokhin Russian Cancer Research center ( Site 2013)
Moscow Moskva, 11547, Russian Federation
Russian Scientific Center of Roentgenoradiology ( Site 2011)
Moscow Moskva, 11799, Russian Federation
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 2000)
Saint-Petersburg Sankt-Peterburg, 19775, Russian Federation
Medical institute named after Berezin Sergey ( Site 2009)
St. Petersburg Sankt-Peterburg, 19775, Russian Federation
Sverdlovsk Regional Oncology Hospital ( Site 2012)
Ekaterinburg Sverdlovskaya Oblast, 62003, Russian Federation
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 2001)
Kazan Tatarstan, Respublika, 42002, Russian Federation
Hospital Universitario Quiron Madrid ( Site 1601)
Pozuelo de Alarcon Madrid, 28223, Spain
Hospital Universitario La Fe ( Site 1603)
Valencia Valenciana, Comunitat, 46206, Spain
Hospital General Universitari Vall d Hebron ( Site 1602)
Barcelona , 08035, Spain More Info
Study Coordinator
Contact
+34934894158
Hospital General Universitario Gregorio Maranon ( Site 1604)
Madrid , 28009, Spain More Info
Study Coordinator
Contact
+34914265134
Hopitaux Universitaires de Geneve HUG ( Site 1706)
Geneva Geneve, 1211, Switzerland More Info
Study Coordinator
Contact
+41223729881
Universitaetsspital Zuerich ( Site 1700)
Zuerich Zurich, 8091, Switzerland More Info
Study Coordinator
Contact
+41442558902
Tri-Service General Hospital ( Site 3300)
Taipei City Taipei, 114, Taiwan More Info
Study Coordinator
Contact
+886-2-8792-3311ext13899
Taipei Veterans General Hospital ( Site 3301)
Taipei , 11217, Taiwan More Info
Study Coordinator
Contact
+886-2-2875-7865
Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 2105)
Adana , 01250, Turkey More Info
Study Coordinator
Contact
+903223444444
Hacettepe University Medical Faculty ( Site 2100)
Ankara , 06100, Turkey More Info
Study Coordinator
Contact
+9031230543304336
Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital ( Site 2101)
Ankara , 06200, Turkey More Info
Study Coordinator
Contact
+90 312 336 09 09
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2116)
Istanbul , 34722, Turkey More Info
Study Coordinator
Contact
905063509061
Kartal Training and Research Hospital ( Site 2102)
Istanbul , 34890, Turkey
I.E.U. Medical Point Hastanesi ( Site 2115)
Izmir , 35520, Turkey More Info
Study Coordinator
Contact
+902323995050
Erciyes University Medical Faculty ( Site 2109)
Kayseri , 38030, Turkey More Info
Study Coordinator
Contact
+903522076666
Sakarya Universitesi Tip Fakultesi Hastanesi ( Site 2114)
Sakarya , 54290, Turkey More Info
Study Coordinator
Contact
+905052014666
Medical center Medikal Plaza of Ecodnipro LLC ( Site 2207)
Dnipro Dnipropetrovska Oblast, 49055, Ukraine
Regional Centre of Oncology-Thoracic organs ( Site 2202)
Kharkiv Kharkivska Oblast, 61070, Ukraine
Ukrainian Center of Tomotherapy ( Site 2206)
Kropyvnitskiy Kirovohradska Oblast, 25011, Ukraine
Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2205)
Kapitanivka Village Kyivska Oblast, 08111, Ukraine
Medical Center Asklepion LLC ( Site 2208)
Khodosivka Kyivska Oblast, 08173, Ukraine
Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2203)
Kyiv Kyivska Oblast, 03126, Ukraine
Kyiv City Clinical Oncology Centre ( Site 2200)
Kyiv , 03115, Ukraine
University Hospitals Bristol NHS Foundation Trust ( Site 1802)
Bristol Bristol, City Of, BS2 8, United Kingdom More Info
Study Coordinator
Contact
+447884216871
Royal Free London NHS Foundation Trust ( Site 1813)
London Camden, NW3 2, United Kingdom More Info
Study Coordinator
Contact
02077940500
Weston Park Hospital ( Site 1801)
Sheffield Derbyshire, S10 2, United Kingdom More Info
Study Coordinator
Contact
+441142265913
Clatterbridge Cancer Center NHS FT ( Site 1800)
Liverpool England, L7 8Y, United Kingdom More Info
Study Coordinator
Contact
+441515565723
Lancashire Teaching Hospitals NHS Foundation Trust ( Site 1809)
Preston Lancashire, PR2 9, United Kingdom More Info
Study Coordinator
Contact
+441772523002
Leicester Royal Infirmary ( Site 1811)
Leicester Leicestershire, LE1 5, United Kingdom
University College London Hospital NHS Foundation Trust ( Site 1806)
London London, City Of, NW1 2, United Kingdom More Info
Study Coordinator
Contact
+447929450961
Guy s and St Thomas Hospital NHS Foundation Trust ( Site 1808)
London London, City Of, SE1 9, United Kingdom More Info
Study Coordinator
Contact
+02071882006
Norfolk and Norwich University Foundation NHS Trust ( Site 1805)
Norwich Norfolk, NR4 7, United Kingdom
Oxford University Hospitals NHS Foundation Trust ( Site 1812)
Oxford Oxfordshire, OX3 7, United Kingdom More Info
Study Coordinator
Contact
+441865235206
Darlington Memorial Hospital NHS Trust ( Site 1810)
Darlington , DLX 6, United Kingdom
Mount Vernon Hospital ( Site 1803)
Northwood , HA6 2, United Kingdom More Info
Study Coordinator
Contact
+441438284298

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

530

Study ID:

NCT03924869

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.